

CV Form

Name(中/英文)	許美鈴 Meei-Ling Sheu	
Affiliation(s)(中/英文)	國立中興大學/National Chung Hsing University (NCHU), Taichung, Taiwan	
Current Position Title	Lifetime Distinguished Professor and Director, Institute of Biomedical Sciences, College of Life Sciences.	
E-mail/Phone Number	mlsheu@nchu.edu.tw Tel: +886-4-23592525 ext 44020912888002	
Personal Website	https://biomed.nchu.edu.tw/node/352	

個人簡歷 (No more than an A4 size paper)

Education/Training:

- 2000/09-2005/01 Ph.D. Institute of Toxicology College of Medicine, National Taiwan University, Taiwan
- 1997/09-1999/06 MS, Institute of Anatomy, National Yang-Ming University.
- 1990/09-1993/06 BS, Department of Medical Technology, Chung Shan Medical University, Taiwan

Professional and Research Experience:

- 2022/08-2026/07 Lifetime Distinguished Professor, NCHU
- 2018/08-2022/07 Distinguished Professor, NCHU
- 2014/02-present Professor, Institute of Biomedical Sciences, NCHU
- 2014/02-present Distinguished Research Fellow, Department of Medical Research, Taichung Veterans General Hospital (VGHTC), Taichung, Taiwan
- 2011/02-2014/01 Associate Professor, Institute of Biomedical Sciences, NCHU
- 2007/02-2011/01 Assistant Professor, Institute of Biomedical Sciences, NCHU
- 2005/08-2007/01 Assistant Professor, School of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taiwan

Awards and Honors:

- 12th President of Toxicology Society of Taiwan (TSTA)
- 2014, 2016, 2018 Outstanding Researcher, Department of Medical Research, VGHTC
- 2014 Excellent Laboratory of Genetic Medicine Education Promotion
- 2014 The 6th Asia-Pacific Bayer Chinese Diabetes Forum - ABCD Best Basic Research Award
- 2014 Outstanding Researcher Young Scientist Award, NCHU

Selected Publications:

1. TPL2 Promotes Gastric Cancer Progression and Chemoresistance Through a Hypoxia-Induced Positive Feedback Loop with PPAR δ . Lan KL, Lai DW, Yang CN, Pan HC, Ou HT, Yu SI, Hsieh TC, Ye YL, Chan CY, Chou KL, Wu SM, Shen LW, Shen CC, Chen L, Liu SH, Chiu CS, Arbiser JL, [Sheu ML*](#). [Int J Biol Sci](#). 2025 Sep 12;21(13):5874-5890.
2. Melatonin Ameliorate neuroinflammation in activated microglia through the Aryl hydrocarbon-Nrf2 axis. [Sheu ML](#), Yang CN, Pan LY, Sheehan J, Pan LY, You WC, Wang CC, Chen YJ, Chen HS, Pan HC. [Int J Biol Sci](#). 2025 Jun 9;21(9):3917-3933.
3. Honokiol inhibits gastric cancer via tumor microenvironment modulation: a bioinformatics and single-cell analysis. Yu SI, Cheng YC, Ye YL, Hsieh TC, Chan CY, Lin YL, Chueh HJ, Tseng YH, Chang KW, [Sheu ML*](#). [Sci Rep](#). 2025 Nov 25;15(1):41997.
4. Melatonin Enhanced Microglia M2 Polarization in Rat Model of Neuro-inflammation Via Regulating ER Stress/PPAR δ /SIRT1 Signaling Axis. Pan HC, Yang CN, Lee WJ, Sheehan J, Wu SM, Chen HS, Lin MH, Shen LW, Lee SH, Shen CC, Pan LY, Liu SH, [Sheu ML*](#). [J Neuroimmune Pharmacol](#). 2024 Mar 26;19(1):11.
5. Targeting histone deacetylase-3 blocked epithelial-mesenchymal plasticity and metastatic dissemination in gastric cancer. Wu SM, Jan YJ, Tsai SC, Pan HC, Shen CC, Yang CN, Lee SH, Liu SH, Shen LW, Chiu CS, Arbiser JL, Meng M, [Sheu ML*](#). [Cell Biol Toxicol](#). 2023 Oct;39(5):1873-1896.
6. Aryl hydrocarbon receptor deficiency augments dysregulated microangiogenesis and diabetic retinopathy. Lee WJ, Lin KH, Wang JS, Sheu WH, Shen CC, Yang CN, Wu SM, Shen LW, Lee SH, Lai DW, Lan KL, Tung CW, Liu SH, [Sheu ML*](#). [Biomed Pharmacother](#). 2022 Nov;155:113725.
7. Aggravation of pulmonary fibrosis after knocking down the aryl hydrocarbon receptor in the insulin-like growth factor 1 receptor pathway. Wu SM, Tsai JJ, Pan HC, Arbiser JL, Elia L, [Sheu ML*](#). [Br J Pharmacol](#). 2022 Jul;179(13):3430-3451.
8. Therapeutic Potential of Tpl2 (Tumor Progression Locus 2) Inhibition on Diabetic Vasculopathy Through the Blockage of the Inflammasome Complex. Sheu WH, Lin KH, Wang JS, Lai DW, Lee WJ, Lin FY, Chen PH, Chen CH, Yeh HY, Wu SM, Shen CC, Lee MR, Liu SH, [Sheu ML*](#). [ArteriosclerThrombVasc Biol](#). 2021 Jan;41(1):e46-e62.
9. Exploiting Honokiol-induced ER stress CHOP activation inhibits the growth and metastasis of melanoma by suppressing the MITF and β -catenin pathways. Chiu CS, Tsai CH, Hsieh MS, Tsai SC, Jan YJ, Lin WY, Lai DW, Wu SM, Hsing HY, Arbiser JL, [Sheu ML*](#). [Cancer Lett](#). 2019 Feb 1;442:113-125.
10. TPL2 (Therapeutic Targeting Tumor Progression Locus-2)/ATF4 (Activating Transcription Factor-4)/SDF1 α (Chemokine Stromal Cell-Derived Factor- α) Axis Suppresses Diabetic Retinopathy. Lai DW, Lin KH, Sheu WH, Lee MR, Chen CY, Lee WJ, Hung YW, Shen CC, Chung TJ, Liu SH, [Sheu ML*](#). [Circ Res](#). 2017 Sep 1;121(6):e37-e52.
11. Melatonin set out to ER stress signaling thwarts epithelial mesenchymal transition and peritoneal dissemination via calpain-mediated C/EBP β and NF κ B cleavage.
12. Wu SM, Lin WY, Shen CC, Pan HC, Keh-Bin W, Chen YC, Jan YJ, Lai DW, Tang SC, Tien HR, Chiu CS, Tsai TC, Lai YL, [Sheu ML*](#). [J Pineal Res](#). 2016 Mar;60(2):142-54.